Genes to Biogen, Noncoding RNAs to Alnylam, Science to Innovation
About the speaker
Philip A. Sharp
Institute Professor, Massachusetts Institute of Technology; Member of the Department of Biology and Koch Institute for Integrative Cancer Research
Phillip A. Sharp is Institute Professor at the Massachusetts Institute of Technology and member of the Department of Biology and the Koch Institute for Integrative Cancer Research.
He joined the Center for Cancer Research (now the Koch Institute) in 1974 and served as its director for six years, from 1985 to 1991, before taking over as head of the Department of Biology, a position he held for the next eight years. In 2000 he founded the McGovern Institute for Brain Research and served as its director until 2004.
His research interests have centered on the molecular biology of gene expression relevant to cancer and the mechanisms of RNA splicing. His landmark work in 1977 provided the first indications of “discontinuous genes” in mammalian cells. The discovery fundamentally changed scientists’ understanding of gene structure and earned Dr. Sharp the 1993 Nobel Prize in Physiology or Medicine. Currently, his work is focused on the biology and Dr. Sharp has authored over 400 papers. He is an elected member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, the American Philosophical Society, and the Royal Society, UK. Among his numerous awards are the Gairdner Foundation International Award, the Lasker Basic Medical Research Award and the National Medal of Science. His long list of service includes member of PCAST, the presidency and now Chair of the Board of the AAAS and Chair of the Scientific Advisory Committee, SU2C Project, AACR.
A native of Kentucky, Dr. Sharp earned a B.A. degree from Union College, Barbourville, KY, and a Ph.D. in chemistry from the University of Illinois, Champaign-Urbana. Dr. Sharp is a co-founder of Biogen (now Biogen Idec) and Alnylam Pharmaceuticals.